Olaris leverages the fields of metabolomics and machine learning to develop innovative in vitro diagnostics aimed at enhancing patient care and treatment efficacy. By focusing on the identification of "biomarkers of response" (BoR), Olaris seeks to tailor medical treatments to individual patients based on their unique molecular profiles. This precision medicine approach allows healthcare providers to determine which therapies are most likely to benefit specific patients, thereby optimizing treatment outcomes and minimizing the risk of adverse effects. The company emphasizes the importance of understanding the molecular makeup of patients, which includes various biomarkers such as DNA, RNA, proteins, and metabolites, to explain the variability in treatment responses among individuals.

Founded in 2014, Olaris is committed to transforming healthcare through data-driven solutions and collaborative research. The company's vision is to create a superior healthcare system by empowering patients, providers, and payers with the information needed to make informed treatment decisions. By focusing on the development of BoRs, Olaris aims to address the challenges of "imprecision medicine," where many patients do not benefit from standard drug therapies. Through its advanced technologies and unique products, Olaris strives to provide a clearer understanding of individual healthcare futures, ultimately leading to more effective and personalized treatment strategies.

United States

Developing metabolomics assays and machine learning algorithms to produce “Biomarkers of Response” (BoR) that differentiate drug responders (R) from non-responders (NR).

Olaris

Company Details